

10/2254

F0 RJL83



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.  
Serial No. : Unassigned  
Filed : Unassigned  
For : Gene Therapy by Administration of  
Genetically Engineered CD34<sup>+</sup> Cells  
Obtained from Cord Blood  
Group : Unassigned (EF116368847U)  
Examiner : Unassigned

Honorable Commissioner of  
Patent and Trademarks  
Washington, D.C. 20231

"Express Mail" Mail Label Number  
Date Of Deposit April 8, 1994

I hereby certify that this paper or fee is being  
deposited with the United States Postal Service "Express  
Mail Post Office to Addressee" service under 37 CFR  
1.10 on the date indicated above and is addressed to  
the Commissioner of Patents and Trademarks, Washington, D.C.

*Colleen Maroney*  
(Type or Print Name of Person Mailing Paper or Fee)  
*Colleen Maroney*  
(Signature of Person Mailing Paper or Fee)

SIR:

Enclosed please find the following:

1. Application (4 independent claims, 26 total);
2. Statement Under 37CFR1.821(f);
3. Information Disclosure Statement with references;
4. Computer disc;
5. Check on the amount of \$916.00; and
6. Date Stamped Receipt Card.

If any additional fees are incurred, please charge Deposit  
Account No. 03-0678.

Respectfully submitted,

*Raymond J. Lillie*  
Raymond J. Lillie  
Reg. No. 31,778

FO RJL79



#984  
02-14-95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.  
Serial No. : Unassigned  
Filed : Unassigned  
For : Gene Therapy by Administration of  
Genetically Engineered CD34<sup>+</sup> Cells  
Obtained from Cord Blood  
Group : Unassigned  
Examiner : Unassigned

Honorable Commissioner of  
Patent and Trademarks  
Washington, D.C. 20231

SIR:

In keeping with Applicants' duty under 37CFR1.56 to disclose information material to the patentability of the above-identified application, the following references, copies of which are enclosed, are hereby made of record.

1. U.S. Patent No.: 5,192,553, Boyse, et al., March 9, 1993;
2. Miller, et al., Biotechniques, Vol. 7, No. 9, pgs 980-990 (1989);
3. Hock, et al., Blood, Vol. 74, No. 2, pgs. 876-881 (August 1, 1989);
4. Moritz, et al., J. Exp. Med., Vol. 178, pgs. 529-536 (August 1993);

The above references also are listed on the attached Form PTO-1449. It is respectfully requested that the Examiner consider these references.

Respectfully submitted,

Raymond J. Lillie  
Reg. No. 31,778

F0 RJL78



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Kohn, et al.  
Serial No. : Unassigned  
Filed : Unassigned  
For : Gene Therapy by Administration of  
Genetically Engineered CD34<sup>+</sup> Cells  
Obtained from Cord Blood  
Group : Unassigned  
Examiner : Unassigned

Honorable Commissioner of  
Patent and Trademarks  
Washington, D.C. 20231  
BOX SEQUENCE

STATEMENT UNDER 37 CFR1.821(f)

SIR:

Pursuant to 37 CFR1.821(f), please be advised that the paper  
and computer readable copies of the sequence listing are the same.

Respectfully submitted,

Raymond J. Lillie  
Reg. No. 31,778